AI assistant
Sending…
Neurogene Inc. — Director's Dealing 2020
Oct 20, 2020
33497_dirs_2020-10-20_7a88f59e-a0c2-4713-9642-7e38a1b6641c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2020-10-19
Reporting Person: Vance Holly (General Counsel)
More from Neurogene Inc.
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Regulatory Filings
2026
Mar 24
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24